| 1 | The PET tracer [
<sup>11</sup>
C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease | 13.1 | 14 | Citations (PDF) |
| 2 | Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist | 3.9 | 13 | Citations (PDF) |
| 3 | Highlights of C (sp<sup>2</sup>)–H hydrogen isotope exchange reactions | 0.9 | 41 | Citations (PDF) |
| 4 | Synthesis of [<sup>3</sup>H] and [<sup>14</sup>C]genipin | 0.9 | 1 | Citations (PDF) |
| 5 | Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases | 6.9 | 32 | Citations (PDF) |
| 6 | Hydrogen isotope exchange labelling: A brief update | 0.9 | 1 | Citations (PDF) |
| 7 | Base metal‐catalyzed hydrogen isotope exchange | 0.9 | 48 | Citations (PDF) |
| 8 | Ni(I)–X Complexes Bearing a Bulky α-Diimine Ligand: Synthesis, Structure, and Superior Catalytic Performance in the Hydrogen Isotope Exchange in Pharmaceuticals | 15.7 | 117 | Citations (PDF) |
| 9 | Synthesis of <sup>3</sup>H, <sup>13</sup>C<sub>2</sub>, <sup>2</sup>H<sub>4</sub><sup>14</sup>C‐SCH 430765 and <sup>35</sup>S‐SCH 500946, potent and selective inhibitors of the NPY<sub>5</sub> receptor | 0.9 | 4 | Citations (PDF) |
| 10 | A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines, and Pharmaceuticals | 15.7 | 153 | Citations (PDF) |
| 11 | Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology | 2.1 | 12 | Citations (PDF) |
| 12 | Site-Selective Nickel-Catalyzed Hydrogen Isotope Exchange in <i>N</i>-Heterocycles and Its Application to the Tritiation of Pharmaceuticals | 12.7 | 77 | Citations (PDF) |
| 13 | Synthesis of <scp><sup>3</sup>H</scp>, <scp><sup>2</sup>H<sub>4</sub>,</scp> and <scp><sup>14</sup>C‐MK</scp> 3814 (preladenant) | 0.9 | 5 | Citations (PDF) |
| 14 | Twelfth International Isotope Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds (IIS2015) | 0.9 | 0 | Citations (PDF) |
| 15 | Iron-catalysed tritiation of pharmaceuticals | 40.1 | 349 | Citations (PDF) |
| 16 | Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand | 4.4 | 11 | Citations (PDF) |
